These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985 [TBL] [Abstract][Full Text] [Related]
27. Acute pisa syndrome and pharnygolaryngeal dystonia due to ziprasidone. Duggal HS J Neuropsychiatry Clin Neurosci; 2008; 20(1):108-9. PubMed ID: 18305296 [No Abstract] [Full Text] [Related]
28. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge. Gray NS Hum Psychopharmacol; 2004 Apr; 19(3):205-7. PubMed ID: 15079855 [TBL] [Abstract][Full Text] [Related]
29. Botulinum toxin in the treatment of tardive dystonia. Chatterjee A; Forrest Gordon M; Giladi N; Trosch R J Clin Psychopharmacol; 1997 Dec; 17(6):497-8. PubMed ID: 9408820 [No Abstract] [Full Text] [Related]
30. Probable association between ziprasidone and worsening hypertension. Villanueva N; Markham-Abedi C; McNeely C; Diaz FJ; de Leon J Pharmacotherapy; 2006 Sep; 26(9):1352-7. PubMed ID: 16945059 [TBL] [Abstract][Full Text] [Related]
31. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. Sallee FR; Kurlan R; Goetz CG; Singer H; Scahill L; Law G; Dittman VM; Chappell PB J Am Acad Child Adolesc Psychiatry; 2000 Mar; 39(3):292-9. PubMed ID: 10714048 [TBL] [Abstract][Full Text] [Related]
32. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Brashear A; Ambrosius WT; Eckert GJ; Siemers ER Mov Disord; 1998 Jan; 13(1):158-61. PubMed ID: 9452343 [TBL] [Abstract][Full Text] [Related]
33. Antipsychotic treatment of psychosis associated with multiple sclerosis. Davids E; Hartwig U; Gastpar M Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):743-4. PubMed ID: 15276702 [TBL] [Abstract][Full Text] [Related]
34. Ziprasidone-induced tardive dyskinesia in a patient without known risk factors. Sinha P; Rao R; Sharan P Natl Med J India; 2007; 20(5):271-2. PubMed ID: 18254531 [No Abstract] [Full Text] [Related]
35. Ziprasidone as a possible cause of cleft palate in a newborn. Peitl MV; Petrić D; Peitl V Psychiatr Danub; 2010 Mar; 22(1):117-9. PubMed ID: 20305605 [TBL] [Abstract][Full Text] [Related]
36. An open-label study of botulinum toxin A for treatment of tardive dystonia. Tarsy D; Kaufman D; Sethi KD; Rivner MH; Molho E; Factor S Clin Neuropharmacol; 1997 Feb; 20(1):90-3. PubMed ID: 9037579 [TBL] [Abstract][Full Text] [Related]
38. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Schindehütte J; Trenkwalder C Clin Neurol Neurosurg; 2007 Feb; 109(2):188-91. PubMed ID: 16949733 [TBL] [Abstract][Full Text] [Related]
39. Pisa syndrome and laryngeal dystonia induced by novel antipsychotics. Miodownik C; Lerner V; Witztum E Isr J Psychiatry Relat Sci; 2011; 48(3):195-200. PubMed ID: 22141144 [TBL] [Abstract][Full Text] [Related]
40. Ziprasidone monotherapy in bipolar II depression: an open trial. Liebowitz MR; Salmán E; Mech A; Dunner D; Johnson AE; Akhtar J; Pratap R J Affect Disord; 2009 Nov; 118(1-3):205-8. PubMed ID: 19264363 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]